2017 Speakers

Speakers Line-up

Speakers Line-up
Alex Matter
CEO
Experimental Therapeutics Centre & D3, A*STAR, Singapore
Anh Bourcet
Associate Director, ASPAC Health Economic & Market Access, Orthopedics
Johnson & Johnson, Singapore
Dr. Asmaa Asim
Head of Regulatory Affairs ROPU South East Asia & South Korea (SEASK)
Boehringer Ingelheim Singapore Pte. Ltd
Akhmal Yusof
Chief Executive Officer
Clinical Research Malaysia, Malaysia
Anu Mahashabde
Senior Director
Global Established Pharma Regulatory Strategy Pfizer, United States
Asita de Silva
Professor in Pharmacology, Director, Clinical Trials Unit, Faculty of Medicine
University of Kelaniya, Sri Lanka

Chris King
Real-World Insights Principal
QuintilesIMS, Singapore

Claire Chin
Associate Director, Regulatory Affairs, SEA & APAC Hub
Allergan Singapore

Cameron Milliner
Head Public Affairs and Patient Advocacy - APAC
Shire, Singapore

Dr C.S. Chen
Executive Director - Cancer Center, Acting Chief of Medicine
Shanghai Jiahui International Hospital, China and and Consultant, Massachusetts General Hospital, Boston, USA
PJ Chen
Vice President, Head of Medical and Clinical Affairs Centre
United BioPharma, Taiwan
Colette Hamilton
Chief Operating Officer
RWE Genesys, United Kingdom
Craig R. Rayner
President
d3 Medicine, A Certara Company,
Adjunct Associate Professor, Monash University - Monash Institute of Pharmaceutical Sciences, Australia

Eva Kopecna
Senior Director Generics Regulatory Affairs Global OTC
Teva Pharmaceuticals International GmbH, Switzerland  

Enrique A. Tayag
Assistant Secretary, Office for Policy and Health Systems
Department of Health, Philippines
Farida Malawi
Head of Public Sales and New Channels, Vaccine Policy & Advocacy and Market Access
Sanofi Pasteur, Indonesia

Gloria Bustos, PhD
Regional Director EMEA and APAC / Global Patient Safety
Baxter Healthcare Corp.

Ivan John Clement
Data Scientist
MSD Innovation Hub, Singapore

Dr. Jutta Hohenhoerst
International Account Manager
Schlafender Hase GmbH, Germany

Jack Wong
Head of Regulatory Affairs – Life Sciences, APAC
Baxter Healthcare (Asia) Pte. Ltd. Secretary of Asia Regulatory Professional Association (ARPA)

John Wilbanks
Chief Commons Officer, Sage Bionetworks, Senior Fellow, Ewing Marion Kauffman Foundation and FasterCures, USA
TEDGlobal 2012 Speaker on “Let’s Pool Our Medical Data” 

Joseph Saba
Chief Executive Officer
Axios International

Jean-François Baladi
Senior Executive, Health Economics and Market Access
Novartis Pharma K.K., Japan
Kevin Cheong
Director, Clinical Operations - Asia
ALMAC Pharmaceutical Services, LLC, Singapore
Kurt Lackovic
CEO
Cancer Trials Australia
Li Ling Liu, Director
Good Registration Management (GRM)Researcher, Deputy Director General Office, Taiwan Food and Drug Administration (TFDA), Taiwan
Dr Michel Mikhail
International Expert in Regulatory Affairs, Germany
Megan Kim
Head of Market Access Korea
Boehringer Ingelheim Pte Ltd, Korea
Michael Hofer
Regional Business Development Manager
DKSH, Asia
Maryline Marquet
APAC Managing Director
Human Care Systems (HCS)

Manish R Garg
Medical Director (Singapore, Malaysia and Brunei)
MSD Pharma (Singapore) Ptd Ltd, Singapore

Mary Pan
Vice President General Management and Business Development Asia Pacific
ICON Plc, Singapore
Mrunalini Jagtap
Data Management Lead
Singapore Institute for Clinical Sciences, A*STAR
Neal Somchand
Senior Consultant
Deallus Consulting, Japan
Nathan Kothandaraman
Lead, Market Access
Johnson & Johnson Sdn Bhd, Malaysia
Qing Xi
Head of Government Affairs, Market Access & Communications
Pfizer, China
Pierce Chow
Professor
Duke-NUS Graduate Medical School/Senior Consultant, Division of Surgical Oncology, National Cancer Centre Singapore / Senior Consultant, Department of Hepatopancreatobiliary/Transplant Surgery, Singapore General Hospital

Robert Kraal
Chief Operations Officer
myTomorrows, Netherlands

Rie Matsui
Director
Regional Labeling Head of Asia, Pfizer Japan Inc, Japan

Roshan Padbidri
Chief Operating Officer (COO)
Anidan Group Pte Ltd, Singapore

Rosalina Saleh
Market Access Lead
PT Boehringer Ingelheim Indonesia

Rakesh Chaurasia
Head-Regulatory Affairs
PT. DEXA-MEDICA, Indonesia

Ritika Bajaj
Associate Director, Global Clinical Trial Operations
MSD Pharmaceuticals, India
Shubhra Bansal
Consulting Learning Partner
Pan Asian Clinical Research Association (PACRA) and Director, Apprentice Learning Solutions

San San Win
Regulatory Affairs Manager
Sanofi Myanmar Co., Ltd

Dr. Silke Nolkemper
Director Consulting APAC (Regulatory Affairs)
EXTEDO, Germany

Sittipong Liamsuwan
Policy & Market Access Director
MSD (Thailand) Ltd., Thailand

Dr. Stephanie Danandjaja, MBA
APAC Medical Director, Established Product
Abbott

KH Tan
Country Head of Legal & Compliance
Novartis, Malaysia

Tay Salimullah
Global Strategic Projects Leader, Real World Evidence
Novartis Pharma AG, Switzerland

Vincenzo Teneggi
Senior Medical Director
D3 (Drug Discovery & Development) A*STAR, Singapore

Vicky HAN
Senior Director
Regulatory Policy Group Lead for Asia Pacific, GRA, Jansen Pharma Singapore

Wei Yuan
Senior Biostatistician
Singapore Clinical Research Institute, Singapore

Yi-Chieh Lin
Officer
Medical Review and Pharmaceutical Benefits Division, National Health Insurance Administration, Ministry of Health and Welfare, Taiwan

Yashaswi Gupta
Medical Science Liaison
Novo Nordisk, Singapore

Yooni Kim
Executive Director, Asia Operations
Novotech, South Korea

Speakers Profile

Speakers Line-up

Alex Matter
CEO
Experimental Therapeutics Centre & D3, A*STAR, Singapore

Alex Matter is CEO of the Experimental Therapeutics Centre since April 2009 and since January 2012 CEO of the newly created D3 platform, A*STAR, Singapore. Previously, he had spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation. Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/Glivec®and more recently, Tasigna®, building and leading the teams that discovered these and several other anticancer drugs as well as one HIV protease inhibitor (Reyataz®) that is marketed by another company.

Dr. Matter received his medical degree from the University of Basel. He also had fellowships at the Swiss National Science Foundation and the Swiss Academy for Medical Sciences. He has published more than 100 scientific articles and several book chapters in the area of oncology and hematology. He is emeritus Professor of the Medical Faculty of the University Basel and an Honorary Adjunct Professor of the Department of Pharmacology, YLL School of Medicine, NUS in Singapore. He is also a member of the Board of the Health Sciences Authorities in Singapore.

He is a member of the American Association for Cancer Research, and member of the Board of Curiox, a Singapore-based start up company. He is also a chair/member of several Scientific Advisory Boards. He is an elected member of the Swiss Academy of Medical Sciences.

Dr. Matter is the recipient of the Life-time Achievement Award from IBC Life Sciences, the 13th Warren-Alpert prize and the AACR-Bruce F. Cain Memorial Award. Recently he was awarded the 2013 Szent-Györgyi Prize from the US National Foundation for Cancer Research.


Asita de Silva
Professor in Pharmacology, Director, Clinical Trials Unit, Faculty of Medicine
University of Kelaniya, Sri Lanka

Professor Asita de Silva has held many positions in academic medicine over the last 24 years. He is a Clinical Pharmacologist, and is currently Professor of Pharmacology at the Faculty of Medicine, University of Kelaniya, Sri Lanka. He established Sri Lanka’s pioneering academic clinical research centre in the same university in collaboration with the Clinical Trial Service Unit, University of Oxford in 2005. Over the last decade, Prof de Silva has lead Sri Lanka’s clinical research initiative through this unit establishing international collaborations. His work has leveraged Sri Lanka’s excellent healthcare structure and clear regulatory policies with great success. Winner of Presidential awards for research, Prof de Silva has been a member of the National Steering Committee for clinical trials in the country for over five years.


Akhmal Yusof
Chief Executive Officer
Clinical Research Malaysia, Malaysia

Dr Akhmal Yusof is an experienced leader from a global research based biopharmaceutical company. He graduated from the Royal College of Surgeons in Ireland in 1992 and practiced medicine in the public and private hospitals for almost 10 years. He later ventured into the medical insurance industry as Medical Manager in one of the biggest medical insurance provider in Malaysia. He was later head hunted to lead the Medical Department in a global research-based biopharmaceutical organization for over 12 years. His main forte in the industry is clinical research management & regulatory, medical and government affairs. He now leads Clinical Research Malaysia (CRM) as the Chief Executive Officer. CRM is a non-profit company owned by the Ministry of Health Malaysia, that functions as a one stop centre for industry-sponsored research.


Dr. Asmaa Asim
Head of Regulatory Affairs ROPU South East Asia & South Korea (SEASK)
Boehringer Ingelheim Singapore Pte. Ltd

Clinician and management trained professional with more than 15 years of experience in health care including pharmaceutical industry and clinical research organization.
Currently provide strategic and operational support to Regulatory Affairs (RA) framework in the SEA and South Korea region.


Anh Bourcet
Associate Director, ASPAC Health Economic & Market Access, Orthopedics
Johnson & Johnson, Singapore

Anh is currently Regional Lead Global Orthopedics, Health Economics & Market Access in Johnson & Johnson Medical Asia-Pacific.
She first joined Janssen France in Medical Affairs, Immunology /CNS. Then, she worked for the French Health Safety Agency on innovative Medical Devices. Her report and recommendations on the regulatory framework paved the way for the European Commission to build their guidelines for Innovations containing nanomaterials.  She returned to Janssen Medical Affairs Asia-Pacific, Immunology, when moving back to Asia. End 2015, she transitioned to the Medical Device sector and to Health Economics & Market Access function. In her current role as Asia-Pacific Lead for Orthopedics, Anh has been driving regional Market Access and Evidence Generation Strategies to demonstrate the value of J&J products in the region, for optimal market access & reimbursement. 

Anh holds a PhD cum laude in Medicinal Chemistry from Paris VI & “Chimie ParisTech” Universities (France), and an Executive Master in Health Industry Management, ESSEC Business School (France).
With about 10 years of experience in healthcare, Anh is passionate about patient outcomes, education and new technology solutions to improve patient care.


Claire Chin
Associate Director, Regulatory Affairs, SEA & APAC Hub
Allergan Singapore

Claire Chin holds a Master of Pharmacy from UCL School of Pharmacy, University of London. With more than 12 years of experience in the healthcare industry in Asia and Europe, Claire has diverse global regulatory experience and supported a wide range of therapeutic areas that cover both pharmaceutical products and medical devices. Apart from regulatory affairs, she has also been instrumental in building up the pharmacovigilance function in one of her previous roles.


Chris King
Real-World Insights Principal
QuantilesIMS, Singapore

As the Principal of Real-World Insights Solutions in APAC at QuintilesIMS, Chris King is leading the direction of next generation RWE offerings and services in the region. He is also the region’s therapeutic expert for oncology related consulting engagements.

Mr King has more than 15 years of extensive experience, and achievements in life science consulting. Prior to joining QuintilesIMS, Chris King was directly responsible for product development, team leadership, and client servicing for IPSOS’s European Oncology Monitor. At Datamonitor’s Healthcare consulting firm, he worked on various global pharmaceutical and biotech consultancy jobs in both global and emerging markets to support the successful launch of new products.

He holds a Bachelor of Arts from the University of British Columbia and an MBA from the London Business School.


Colette Hamilton
Chief Operating Officer
RWE Genesys, United Kingdom

Colette is CEO of RWE Genesys, a provider of digitally enabled real world evidence solutions.  RWE Genesys is pioneering patient engagement to bring new insights to evidence based decision makers.   As a healthcare industry expert in health economics and outcomes research, Colette has in depth understanding of evidence requirements for patient access around the world.  Colette has a background in life science business development, health service management and healthcare consulting with one of the world’s big five accounting firms.  Colette has managed health economics and outcomes research projects in more than 26 countries.  She has an MBA in international healthcare policy and economics and an MSc in psychology.


Cameron Milliner
Head Public Affairs and Patient Advocacy - APAC
Shire, Singapore

With more than 15 years of experience within government, consultancy and multinational corporations, Cameron has a deep understanding of the development and implementation of public policy, stakeholder management and advocacy.

He currently works as the Head Public Affairs and Patient Advocacy for Shire, a biopharmaceutical company specialising in rare and specialty conditions, with responsibility for the Asia Pacific Region.  Prior to this, Cameron worked for a Pharmaceutical and Medical Device Company, as a Director of a Corporate Affairs consultancy and as a Senior Advisor to a Health Minister in an Australian State Government.

Cameron holds a Bachelor of Commerce (Marketing and Industrial Relations) from Griffith University and has been appointed a Visiting/Honorary Fellow of the Murdoch University School of Research and Innovation and the Centre for Comparative Genomics.  In addition to these roles he also holds an Honorary Fellowship of the McKell Institute, a public policy think tank specalising in social policy.


PJ Chen
Vice President, Head of Medical and Clinical Affairs Centre
United BioPharma, Taiwan

PJ Chen is VP of global clinical development and president of Taiwan at United Neuroscience. United Neuroscience (UNS) is a clinical-stage biotech company dedicated to the development of innovative therapeutics for Alzheimer’s Disease and other neurodegenerative disorders. In this role, PJ oversees the clinical development programs and business operation in Taiwan office.

PJ joined UNS with experiences in early phase drug development at Harvard medical school (HMS) and Massachusetts General Hospital (MGH), drug development and project/data management with AstraZeneca and project management, clinical monitoring and commercial operation functions in CRO industry including PPD, Parexel and WuXiPRA. PJ received his graduate degree from Massachusetts Institute of technology in biomedical imaging.


Craig R. Rayner
President
d3 Medicine, A Certara Company,
Adjunct Associate Professor, Monash University - Monash Institute of Pharmaceutical Sciences, Australia

Dr. Rayner has more than 15 years of drug development experience. His past appointments include leadership roles in Clinical Pharmacology and Early development (Roche), Clinical development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche) and as an academic researcher in clinical pharmacology and infectious disease research (Monash University).

Dr. Rayner has extensive experience in early and late development of therapeutics, regulatory interaction experience with all major global health authorities, multiple filings and accountability for numerous due diligences, active support of negotiations, deal making and integration activities. He holds an Adjunct Associate Professorship in Pharmaceutical Science (Monash University), and is broadly published in clinical pharmacology and also infectious diseases.


Dr C.S. Chen
Executive Director - Cancer Center, Acting Chief of Medicine
Shanghai Jiahui International Hospital, China and and Consultant, Massachusetts General Hospital, Boston, USA

Prior to joining Jiahui, Dr. Chen was the Professor of Medicine, Pediatrics and Basic Science; Chief, Division of Medical Oncology & Hematology and Bessie Emanuel Endowed Chair for Clinical Oncology Research at Loma Linda University and Medical Center, in California, USA. 

Dr. Chen graduated from China Medical University and completed Ph.D. and postdoctoral training in molecular oncology (Pathobiology Program) at University of Minnesota, USA.  He received his Internal Medicine internship and residency training at the Washington University Medical Center, Barnes Hospital in St Louis, Missouri followed by Medical Oncology fellowship at Fred Hutchinson Cancer Research Center (FHCRC) and University of Washington in Seattle.  In 1997, he was the recipient of first E Donnell Thomas Award at FHCRC for his research work.

During 98’-03’, He launched stem cell transplant program and served as the director for the adult transplant program at LLU, California, USA.  By 03’, Dr. Chen was recruited by National University of Singapore (NUS) and National University Hospital as a senior consultant and associate professor.  He continued clinical practice, expanded stem cell transplant program and translational research. 

In 2007, Dr. Chen was recruited back to LLU, California as the chief of the division of hematology and medical oncology and facilitated the opening of a state-of-art cancer center.  He also launched the LLU Cancer Center Biospecimen Bank in 08’ and established multiple research collaboration in translational medicine.

During his nearly 20 years at Loma Linda and Singapore, in addition to multiple leadership role in program development, Dr. Chen was the primary investigator for multiple clinical research trials including malignant hematology and solid tumors over the two decades, and has published more than 65 peer-reviewed papers in PNAS, Leukemia, Blood, Cancer Research, Oncotarget, and Journal of Clinical Oncology.


Enrique A. Tayag
Assistant Secretary, Office for Policy and Health Systems
Department of Health, Philippines

Enrique A. Tayag is presently serving as Assistant Secretary for the Office for Policy and Health Systems, under the Department of Healt for Philippines. He provides overall-direction and oversight to the following Bureaus: Health Policy Development and Planning Bureau, Bureau of International Health Cooperation, Bureau of Local Health Systems Development and Health Human Resource Bureau, and the Pharmaceutical Division. He had previously served as Director in the Bureau of Local Health Systems Development and also the National Epidemiology Center.


Farida Malawi
Head of Public Sales and New Channels, Vaccine Policy & Advocacy and Market Access
Sanofi Pasteur, Indonesia

Farida Malawi is a Sales, Qualified Quality Standard System and Assurance, Regulatory Affairs, Vaccine Public Policy and Government Affairs. She has vast experience that stretch for the past 16 years in Pharmaceutical business in Indonesia for different roles. She also has an extensive background in biotechnology, pharmaceutical and consumer industry businesses supported by project management, continuous improvement platform and leadership skills. She worked at Sanofi Indonesia for 3 years, the last position is Sales Head of Vaccine Division. She graduated as a Pharm.D and certified Pharmacist from University of Indonesia and was awarded Cum Laude in the Master of Business Administration with majority of Strategic Management from University of Gadjahmada. Farida likes to work in the area of market access and public health interface within the healthcare prevention initiatives.


Ivan John Clement
Data Scientist
MSD Innovation Hub, Singapore

Ivan Clement is a data scientist with Merck & Co. (MSD), focused on applying advanced analytics, machine learning, and mathematical modeling techniques on pre-clinical and -omics data, health economics read-outs, and novel forms of real-world evidence.

He has held research attachments with the Massachusetts Institute of Technology (MIT), the Singapore-MIT for Research and Technology (SMART), and the Mechanobiology Institute, building experimental and computational platforms to interrogate cancer pathophysiology on multiple biological scales – using cutting-edge techniques in machine learning and mathematical modeling.

He was formerly a computational scientist with Eli Lilly and Company, building models of drug distribution and action in support of drug development programs and FDA regulatory submissions. While in Lilly, he has also supported the development and the application of systems pharmacology modeling in diabetes and immuno-oncology drug development programs.


Joseph Saba
Chief Executive Officer
Axios International

Dr. Joseph Saba is Co-Founder and Chief Executive Officer of Axios International. Under his leadership, the company has developed several innovative healthcare access models for emerging markets and implemented access programs throughout Asia, the Middle East, Africa and Latin America. Dr. Saba is a French Lebanese medical doctor specialized in infectious disease, health management and statistics. He previously served in senior clinical research and development roles at the World Health Organization, UNAIDS and the Joint United Nations Program on HIV/AIDS. Dr. Saba holds a medical degree, along with a certificate of Medical Statistics, from the University Paris VI (France), is a graduate of St. Joseph University (Beirut, Lebanon), and holds a Master of Communications and Medical Management (MSc) from the Superior Business School (Paris, France). He has been featured in the Wall Street Journal, International Herald Tribune, Newsweek and Pharmaceutical Executive, among others.


Dr. Jutta Hohenhoerst
International Account Manager
Schlafender Hase GmbH, Germany

Dr. Jutta Hohenhoerst has more than 20 years of experience in the pharmaceutical business. She gathered experience in different departments from Supply Chain Management to Strategic Marketing at F. Hoffmann-La Roche, AstraZeneca and Fresenius Kabi. While working for QuintilesIMS for 7 years she supported pharma and medical device companies through strategic consulting projects. Today, Dr. Hohenhoerst possesses an extremely good network globally and has been working for Schlafender Hase GmbH since 2012.


Kurt Lackovic
CEO
Cancer Trials Australia

Dr Kurt Lackovic is CEO of Cancer Trials Australia, a not-for-profit enabler of clinical trials, incorporated in 2003.  Kurt has a PhD in chemistry and post-doc experience in medical genomics and early stage drug discovery.  Kurt has extensive expertise in leading complex academic and clinical programs, strong connections to industry, and strategic linkages to senior executives in Government and major teaching Hospitals. Kurt is a Graduate of the Australian Institute of Company Directors, and a member of the Licensing Executives Society of Australia & New Zealand and AusBiotech.


Kevin Cheong
Director, Clinical Operations - Asia
ALMAC Pharmaceutical Services, LLC, Singapore

Kevin Cheong is Director, Clinical Operations at Almac, where he oversees operational staff and service delivery from the company’s operational centers in Singapore and Japan.  Being one of the pioneer member of the Singapore leadership team, Kevin was involved in the setting up of the Almac’s Singapore Facility. The facility is the first in Singapore to provide Primary Production Services to the region.

Prior to joining Almac, Kevin served as the Operations Director for Fisher Clinical Services, where he managed financial and operational performance for all clinical studies and grew key accounts by more than 50 percent.  Kevin also managed and expanded Fisher’s regional Singapore facility, established cold chain operations, and implemented a new building management system that enabled web-based visibility and wireless temperature and humidity monitoring.

A frequent speaker, Kevin has led workshops on supply chain management and optimization, continuous process improvement, and radio-frequency identification in the logistics industry.

Kevin holds a Bachelor of Science in Computing from the University of Portsmouth and is certified in Production and Inventory Management by the American Production and Inventory Control Society.


Manish R Garg
Medical Director (Singapore, Malaysia and Brunei)
MSD Pharma (Singapore) Ptd Ltd, Singapore

Manish Garg is a physician with MD in Clinical Pharmacology. He is currently Medical Director for MSD Malaysia, Singapore and Brunei. He has a rich experience with Pharmaceutical Industry for more than 13 years. He has actively contributed in Medical Affairs (MA) in both innovator (Bayer and Abbott) and Generic companies (Unichem and Glenmark).  He has been in a Country MA Role and Asia Pacific Regional Therapy Area Expert (Oncology) Role. Prior to joining Pharmaceutical Industry he was in clinical practice treating patients in outpatient setting. He has also worked as a lecturer in a Medical School attached to a Tertiary Hospital. He has been involved in research and has several publications to his credit in peer reviewed journals during post graduate period. He also has received awards and gold medals for his research.


Dr Michel Mikhail
International Expert in Regulatory Affairs, Germany

Dr. Michel Mikhail has more than 25 years Pharmaceutical Industry experience in Senior roles, with a track record of achievement in R & D and International Regulatory Affairs in large multinational Research-based pharmaceutical companies as well as in the Generic & Biosimilars industry. He has served on the Safety working group and Efficacy working Group of the European Federation of Pharmaceutical Industry associations (EFPIA), the Regulatory Group of the European branch of the Pharmaceutical Research and Manufacturers of America (PhRMAEurope), on the Regulatory and Scientific Affairs Group of the uropean Generic medicines Association (EGA) amongst others. He is also a member of the organisation for Professionals in Regulatory Affairs (TOPRA).


Megan Kim
Head of Market Access Korea
Boehringer Ingelheim Pte Ltd, Korea

Megan started her career in the regulatory affairs area and served for license in and out, business development, marketing and business strategies as well as Market Access in Pharma industry for more than 25years. She has worked for Bayer Korea as BD director, Head of Marketing and Commercial in Pierre Fabre Medicament in Korea, then for Boehringer Ingelheim Korea as Head of BD and Market Access from 2009 thru 2014. She relocated to the BI Regional office in Singapore as Head of Market Access responsible for the area of Southeast Asia and Korea from 2014 thru 2016.  She returned back to Korea office and currently positioned as Head of Market Access Beohringer Ingelheim Korea.

Megan Kim majored in pharmacy at ChungAng University in Korea and received the master’s degree in Finance at Korea University and then, an MBA at the Booth School of Business, the University of Chicago.


Mary Pan
Vice President General Management and Business Development Asia Pacific
ICON Plc, Singapore

 

 

  • Head of APAC for ICON, in charge of a region of 13 countries and 2900 employees
  • 20 years’ leadership in Global drug development and Medical Affairs (Pfizer, Crucell / J&J) based out of the USA, EU, and Asia
  • Grew global CRO in Asia from employee #1 to 150 and 8 countries in 2.5 years as managing director
  • Head of Strategy and Business Development for $1.2 Billion portfolio
  • Pharma, Biotech, Medical Device, CRO experience
  • MD ed, LLM (law), MBA, PMP, Six Sigma Black Belt

Mrunalini Jagtap
Data Management Lead
Singapore Institute for Clinical Sciences, A*STAR

During her previous stints with pharmaceutical and ITES/CRO organizations, Mrunalini has gained expertise in leading global clinical data management projects conducted across US, Europe and Asia-Pacific to successful completion. Currently she is associated with SICS where she is leading data management practices for observational studies in academia. She is passionate about streamlining processes and continuous improvement. Mrunalini has completed Masters in Data Science and Analytics from Royal Holloway University of London, UK and is trained in Lean Six Sigma Black Belt. She is a certified clinical data manager (CCDM) by SCDM and a certified project management professional (PMP) by PMI, USA. Mrunalini has authored five articles and also presented on diverse topics at various international conferences in Singapore, India and Germany.


Michael Hofer
Regional Business Development Manager
DKSH, Asia

Michael is Senior Manager in the Regional Business Development Team of DKSH Business Unit Healthcare. He is responsible for the expansion and innovation of new services as well as developing the business for Value Added Services (VAS) from Market Entry Solutions to Regulatory, Telemarketing & Patient Solutions across Asia. Michael has worked with DKSH since 2007 in various management functions in the areas of Business Development, Marketing, Communications and Branding. He is based in Bangkok, Thailand. Michael Hofer holds a M.A. degree from the University of Zurich in Media Science and Management & Economics.


Maryline Marquet
APAC Managing Director
Human Care Systems (HCS)

Maryline is APAC Managing Director of Human Care Systems (‘HCS’). Globally Since 2008, HCS designs and delivers technology driven therapy management to improve patient initiation, adherence, and persistence.

Prior to HCS Maryline was the head of Strategic Innovation at Becton Dickinson Asia, responsible for growing APAC region’s portfolio for new products and platforms. Prior to BD, she worked at International SOS Singapore where she was Global Director of Product Development and Marketing in Medical Supply Services.

Maryline relocated from Europe in 2015, where she had held a variety of positions in product marketing and project management at Janssen, Pharmaceutical Companies of Johnson and Johnson.  She designed, developed and delivered patient support programs (beyond the pill) in several therapeutic areas: oncology, infectious and metabolic diseases.

Maryline holds a Master of Science and Business from EDHEC and an MBA from INSEAD. Her early career was in consulting and start-up.


Neal Somchand
Senior Consultant
Deallus Consulting, Japan

Neal is a Principal in the Deallus Tokyo office, joining Deallus in January 2016. Neal brings with him over 8 years of experience as a consultant for medical device and pharmaceutical companies.  Neal has managed projects across various geographies – concentrating on Japan and EU5 (UK, France, Germany, Spain, Italy) from a pricing and reimbursement perspective, monitoring the rapidly changing landscapes for client in addition to recommending optimal pricing strategies for new compunds .   

Prior to joining Deallus, Neal worked in London on pricing and market access assessments, delivering recommendations for EU launches.  He had a special interest in orphan drug pricing, and, in addition to EU-5, also worked on projects focused on Central Europe and Scandinavia.  Neal started his career at the Tokyo office of LEK as an Associate Consultant, focusing exclusively on the Japan market assessments and market entry strategy.
Neal holds a Masters in Oncology (with Distinction) from University of Nottingham, UK, and is a fluent speaker of Japanese and English.


Nathan Kothandaraman
Lead, Market Access
Johnson & Johnson Sdn Bhd, Malaysia

Nathan is the current Lead of Market Access at Johnson & Johnson Malaysia. He has over 20 years of wide ranging experience in the Healthcare and Pharmaceutical field as a pharmacist in the government hospital, pharmaceutical manufacturing, community pharmacy and pharmaceutical industry. He won a regional merit award for best regional marketing program in 2004 and global merit award for astounding strategic leadership for the launch of a new novel antipsychotic in 2006.  He has successfully participated and completed up to 24 various courses on leadership, process excellence and marketing excellence in addition to numerous local and international scientific conferences participation. He has a certificate in good clinical practice (GCP) and has been involved extensively in coordinating various clinical trials.

Nathan currently has responsibilities for market access and government affairs in policy engagement and facilitating access for various therapeutic categories.  He also has obtained course certificates in Health Economics and Health Technology Assessment.


Pierce Chow
Professor
Duke-NUS Graduate Medical School/Senior Consultant, Division of Surgical Oncology, National Cancer Centre Singapore / Senior Consultant, Department of Hepatopancreatobiliary/Transplant Surgery, Singapore General Hospital

Pierce Chow is Co-Director (Surgical) of the Comprehensive Liver Cancer Clinic at NCCS and Senior Consultant Surgeon in HPB and Transplant Surgery at SGH. He is concurrently Professor and Course Director at DukeNUS Medical School Singapore, Adjunct Faculty at GIS and Research Director at IMCB.

Pierce has researched extensively on hepatocellular carcinoma (HCC) and leads collaborative research on the genomic heterogeneity of HCC and applications in precision medicine. He co-founded the Asia-Pacific Hepatocellular Carcinoma Trials Group in 1997 and has been the protocol chair of 5 multi-national trials. In 2012 the NMRC conferred him the National Outstanding Clinician-Scientist Award for improving clinical outcomes of patients with his research on Liver Cancer.

Pierce was awarded the NMRC Translational-Clinical Research Grant for the Flagship Program in Liver Cancer in 2016 and has commenced the multi-national PLANET study (Precision Medicine in Liver Cancer Asia-Pacific Network).


Qing Xi
Head of Government Affairs, Market Access & Communications
Pfizer, China

As the Senior Director of Government Affairs, Market Access & Communications of Pfizer China, Mr. XI is responsible for central and local government affairs, market access, policy advocacy, CSR, communications and media relations to support all business and function in China. As a member of Pfizer China Leadership Team, he reports to Regional President of Pfizer China directly.

From Oct. 2009 to Feb. 2016, Mr. XI was the Head of Communications in Pfizer China, leading Communications to develop and implement communication strategies and projects.

Before Pfizer acquired Wyeth in 2009, Mr. Xi was the Public Relation Director of Wyeth China. And before joining Wyeth in 2004, he had been working at Intel China for above 7 years in Public Relation & External Affairs.

He is now co-chairing the Communication Working Group of R&D Based Pharmaceutical Association Committee (RDPAC).

Mr. Xi got his EMBA degree from Shanghai Europe International Business School (CEIBS) and the Bachelor Degree from Shanghai Jiao-Tong University.


Robert Kraal
Chief Operations Officer
myTomorrows, Netherlands

Robert Kraal, MSc, is the COO of myTomorrows, a company that supports physicians and their patients with unmet medical needs with access to pre-approval medicines globally.

Founded on the belief that technological advancements have the potential to radically change healthcare, myTomorrows’ programs are designed to streamline drug development timelines, provide better value to physicians, and facilitate tangible access to life-enhancing medicines.

For the past 20 years Robert has turned technology-driven companies from local start-ups to international best-in-class players. He is passionate about advancing internet-based business models to address a real customer need in complex networks of stakeholder involvement.


Ritika Bajaj
Associate Director, Global Clinical Trial Operations
MSD Pharmaceuticals, India

Dr. Ritika Bajaj is Associate Director, Global Clinical Trial Operations at MSD Pharmaceutical, India and a member of the Indian society for Clinical Research since 2007

Dr. Ritika has over 17 years of clinical Research industry experience. She has held leadership positions with reputed multinational Pharma and Biotech companies like Eli Lilly and Biogen Inc. and has worked in several Therapeutic areas including Diabetes Care, Oncology, critical Care, Neurology and hemophilia contributing to the clinical development and life cycle management of several promising drugs in her career.

Ritika has received her advanced GCP training from the Vienna School of Clinical Research and is also a Six-Sigma green belt in process improvement.

Outside of clinical Operations she has contributed to learning and development of clinical research professionals, in the Asia Pac region through various training programs, and has been a speaker at several national and international forums.


Rakesh Chaurasia
Head-Regulatory Affairs
PT. DEXA-MEDICA, Indonesia

Mr Rakesh Chaurasia has been in the pharmaceutical industry for 25 years. He started his career as a Quality Chemist and held different responsibilities in GMP Compliance, Manufacturing, Quality Assurance, Regulatory Compliance and Drug Regulatory Affairs for Active Ingredients as well as Finished dosage form.

He has worked for companies like Dabur Research (now Fresenius Kabi), JK Drugs & Pharmaceuticals (now Teva), Medicorp Technologies (now Mylan), Cadila Pharma, Intas Pharma and Macleods Pharmaceuticals Limited.

Since Dec 2013 he is associated as Advisor in PT Dexa Medica (Indonesian Pharma Copany) and helping it for Capacity building in Drug Regulatory Affairs function to prepare itself for global expansion. He has a thorough understanding of global regulatory requirements for small molecule pharmaceuticals. He has been actively involved with global Regulatory bodies like US FDA for filing a large number of generic and new drug applications (505[b] [2]); with European agencies for filing generic applications; with WHO Prequalification and so on.

Mr Rakesh Chaurasia has 2 Bachelor Degrees namely a Bachelor of Science from the University of Allahabad and a Bachelor degree in Pharmaceutical Sciences from Indian Institute of Technology (IIT), Benaras Hindu University. He also holds a Diploma in Management from Indira Gandhi National Open University and a Diploma in Intellectual Property Rights from World Intellectual Property Organization (WIPO), Geneva.


Rie Matsui
Director
Regional Labeling Head of Asia, Pfizer Japan Inc, Japan

Rie Matsui is currently Director, Regional Labeling Head for Asia, International Labeling Group, WSR-International and Global Product Information, Pfizer Japan. She has established the Asia Labeling Hub in Pfizer since July 2012 and the Asia Labeling Hub has created the local label updates for more than 20 countries in Asia. She is working with 14 affiliates in Asia.

Previously, she was a Senior Labeling Manager in Regulatory Affairs, Pfizer Japan. She was assigned Japan labeling for global pharmaceutical products within Wyeth Japan (now Pfizer) since 1993. She led responses to support post-marketing label changes in Japan arising from both new data and regulatory requests.  In addition, she has led the development of 10 Japan submission labels for new global products. She has extensive experience working with PMDA and has developed/managed workshops with the PMDA regarding global requirements for labeling, global risk management systems and the impact of these on Japan.  She is a proponent of proactive collaboration between global teams and local teams in the management of labeling and risk management plans prior to PMDA submissions.

Since 2012 she has been a member of the content committee in DIA Japan and she was the program chair for the DIA Japan labeling workshop in February 2016 and a member of the program committee for the DIA Japan risk management workshop in May 2016 as well. Since 2004 she has been a member of the labeling working group of the DIA Regulatory Affairs Special Interest Area Community and was a member of the labeling working group of the Japan Pharmaceutical Manufacturers Association. She has won the 2015 DIA Japan’s Inspire Regional Award. She published a paper entitled “US Prescribing Information: New Requirements” in the Pharmaceutical and Medical Device Regulatory Science.


Roshan Padbidri
Chief Operating Officer (COO)
Anidan Group Pte Ltd, Singapore

Roshan Padbidri has had the opportunity of having assumed a variety of roles in the clinical trial enterprise in the past 14 years. In his former role as Regional Clinical Operations Excellence Consultant of Sanofi Asia-Pacific regional HQ, he was responsible for the clinical operations of medical affairs studies including oversight, execution, budgeting, inspection readiness and quality improvement visits. Currently, he is Vice-President and General Manager of Anidan Group Pte Ltd where he oversees strategy, operations, finance, business growth and development.

As the former Clinical Study Manger of Takeda Global Development and Research Centre (Asia) Pte Ltd, he oversaw global clinical development programmes and focused on study feasibility, protocol development, CRO selection, monitoring, budget management, training and quality management.  

Prior to this appointment, he was Clinical Leader and Manager of Parexel International Sdn Bhd. In this regional role, he was responsible for clinical study assessment and initiation, project implementation, trial performance reporting to the sponsors and financial tracking.

He was the former Manager, Clinical Development of Novartis India Ltd at the International Clinical Research Operations(ICRO). He was responsible for clinical operations, monitoring, SOP writing, systems expert and training coordinator for APAC.

Formerly, he served the term in the training council at the Indian Society of Clinical Research (ISCR) where he developed and delivered training modules for national workshops for advanced GCP courses. He served as visiting faculty at the following institutes; Pharmaceutical Experts Association (PEXA), Institute of Clinical Research India (ICRI), Centre for Advancement in Health Sciences (CAHS) and Academy of Clinical Excellence(ACE).

He has a graduate degree in Microbiology and is a Post graduate in Biochemistry from the university of Mumbai.


Rosalina Saleh
Market Access Lead
PT Boehringer Ingelheim Indonesia

Medical Doctor, 5 years experience as General Practitioner and Lecture, 17 years experienced in pharma industry in Indonesia (medical, sales and marketing). Working in both local and multinational pharma industries in Indonesia (Dexa Medica, Roche, BMS, GSK, Novartis). Currently work in Boehringer Ingelheim Indonesia as Market Access Lead.


Dr. Silke Nolkemper
Director Consulting APAC (Regulatory Affairs)
EXTEDO, Germany

Silke has more than 7 years experience as Regulatory Affairs Manager in the pharmaceutical industry. After starting her career at PharmaLex, she joined Sandoz/HEXAL, where she was accountable for a broad sprectrum of marketing authorisations within EU, Asia Pacific, Latin America and Middle East as well as for some aspects of pharmacovigilance. At EXTEDO, Silke is responsible for the implementation of regulatory updates regarding eSubmission (eCTD, NeeS, eCopy, VNeeS, ASMF, DMF) as well as Planning & Tracking. She provides regulatory advice to both internal colleagues and external customers and she helds training courses.


Sittipong Liamsuwan
Policy & Market Access Director
MSD (Thailand) Ltd., Thailand

Sittipong Liamsuwan has over 15 years in Market Access covering i) Pricing & Reimbursement, ii) Health Economics & Outcome Research, and iii) Top Policy Key Stakeholder Management to define access strategy for patients.

Sittipong has educational background in Pharmaceutical, Political Sciences and Bioengineering as well as professional certifications in Business Intelligent & Research and Market Research

Sittipong has contributed to several multinational pharmaceutical companies and have improved access for patients in several Therapeutic Areas including CVD/ Bone/ Oncology/ Vaccine. He also has initiated access strategy and implementation in deep drive from national to community level

In additional to contributions in the country, Sittipong has held a regional role experience to develop Market Access Training (internal training on Market Access) program and Pricing and reimbursement database and information for Asia Pacific countries.


Dr. Stephanie Danandjaja, MBA
APAC Medical Director, Established Product
Abbott

Stephanie is a physician with experience in working with multinational companies in the US, Indonesia and Singapore for the last 15 years in the areas of Medical Affairs, Clinical Research, Regulatory, Pharmacovigilance and Business Development.  

She joined Aventis Indonesia in 2000 as Medical Manager. In 2003, she became Schering Plough’s Medical & Regulatory Director and was seconded to Global Medical Operations in SP Headquarters, NJ, US. She was also part of the Global Working group for R&D and Medical Affairs merger – combining both functions and streamlining after the merger with Organon. In 2007, she joined Sanofi Indonesia as Medical & Regulatory Director, and then added Business Development into her scope in 2009 – leading M&A and integrating CHC business into the affiliate.

She relocated to Sanofi Asia Regional office in Singapore as Regional Medical Excellence in 2010. In 2013 her role was expanded to cover Strategic Planning and Medical Operations until early this year. She is currently APAC Medical Director for Abbott Established Products, as well as Adjunct Associate Professor in Rutgers School of Health Professions. She is also Steering Committee Advisor for ASEAN Drug Information Associations.


Shubhra Bansal
Consulting Learning Partner
Pan Asian Clinical Research Association (PACRA) and Director, Apprentice Learning Solutions

Ms. Shubhra Bansal is a Consulting Learning Partner - Pan Asian Clinical Research Association (PACRA) and Director- Apprentiice Learning Solutions. Shubhra has been in Pharmaceutical research Industry for 18 years with depth of experience. She holds a Master of Science in Medical Elementology and Toxicology from Hamdard University, New Delhi. Shubhra started her career in University research in 1999 and progressed into clinical research in year 2000. Starting from basics of Clinical research as a Clinical Research Associate , she had reached to the position of Director, Asia Pacific -Clinical Management in a Multinational Organization. She has wide experience of various Therapeutics areas across Asia Pacific countries. During her entire career, Shubhra has been instrumental in leading and providing the support, guidance and mentorship to team members and her reports. She has been leading training for the department across Asia pacific and has worked as core contributor on global training initiatives during her career.

She is a certified Trainer from Life Sciences Skill Sector Council, New Delhi; Member of Indian Society of Clinical Research (ISCR) and Member of Leaders Excellence at Harvard Business Square.


Tay Salimullah
Global Strategic Projects Leader, Real World Evidence
Novartis Pharma AG, Switzerland

Tay is Director Global Pricing and Market Access in Cell and Gene Therapies at Novartis Pharma Switzerland. Responsible for developing the market access strategy; value story; and pricing strategy across multiple indications for one-time potentially curative therapies for patients with relapsed refractory forms of hematological cancers.

Tay recently lead project HARMONY: an external industry leading public-private-partnership to shape outcomes, reimbursement and policy in Europe. HARMONY is the largest big data for better outcomes funded (€40M) programme. The project aims to foster better access and care for patients with various Hematological Malignancies with the use of big data as well as drive R&D efficiency.

Tay joined Novartis in 2013 as Market Access Director Region Europe in General Medicines. Prior to joining Novartis Tay worked at Pfizer for 11 years where he held several positions of increasing responsibilities within commercial, market access and strategy development. In 2009 Tay completed his Global Health Fellowship: in-field healthcare systems experience (USAID) in Malawi to scale eHealth organization to provide HIV solutions for 10% of the population. He has also worked in Asia as market access consultant and for a multibillion dollar private investment group to provide solutions for the low-middle income healthcare consumers across Asia.


Vincenzo Teneggi
Senior Medical Director
D3 (Drug Discovery & Development) A*STAR, Singapore

Vincenzo has more than 25 years global experience of drug development within major pharmaceutical companies as Wellcome, Glaxo-Wellcome, GSK, Novartis and Roche in Europe, North America and Asia Pacific.

He has held a number of positions such as Clinical Medical Expert, Head of Drug Surveillance, Head of Phase II-IV Clinical Research and Head of Early Development & Clinical Pharmacology for Asia Pacific. Through these roles he has gained an extensive and deep knowledge of all phases of clinical drug development in multiple therapeutic areas including cardiovascular, liver, lung diseases, neurosciences, virology and oncology, as well as clinical pharmacology, drug safety/pharmaco-vigilance and biomarker strategy in early clinical trials.

Vincenzo received his medical degree, as well his Lung Disease and Internal Medicine specialist qualifications from the University of Rome “La Sapienza”. He has published scientific papers in major journals and presented at numerous conferences as well as being the co-author of book chapters and named inventor on patent applications.

He is a member of: the Physicians-Surgeons and Dentists Association of Rome, the American Society of Clinical Oncology, the American Society for Clinical Pharmacology and Therapeutics.


Wei Yuan
Senior Biostatistician
Singapore Clinical Research Institute, Singapore

Ms. Wei Yuan is a senior biostatistician from Singapore Clinical Research Institute, a MOH holding academic research organization. Primarily she provides biostatistics support to clinical trials, including study design, protocol development, sample size justification, randomization, database review, statistical analysis plan and report, manuscript writing and publication. She has involved in the first antiviral clinical trial against acute dengue in Singapore and the recently completed randomised clinical trial of prophylactic platelet transfusion for adult dengue patients with thrombocytopenia (ADEPT) published in Lancet medical journal. Ms. Wei also has great interests in health technology assessment and is doing a part time degree with University of York in this topic.


Yooni Kim
Executive Director, Asia Operations
Novotech, South Korea

At Novotech, Dr. Kim is responsible for overseeing Novotech’s operations and project delivery within the Asia region. Dr. Kim is very experienced in Asia’s drug development industry, having managed operations for South Korea, Taiwan, China, Hong Kong, Singapore, Malaysia, Indonesia, Thailand, the Philippines and Japan. Prior to joining Novotech, Dr. Kim was Director of Operations for North Asia at leading global CRO and has worked at various positions in clinical development, medical affairs and pharmacovigilance at GSK. Dr. Kim has spoken widely regarding the current landscape of clinical development in Asia. Dr. Kim is a trained pharmacist and received doctorate degree of medicine from Seoul National University, specializing in Preventive Medicine and Epidemiology.


Yi-Chieh Lin
Officer
Medical Review and Pharmaceutical Benefits Division, National Health Insurance Administration, Ministry of Health and Welfare, Taiwan

  • Associate Technical Specialist, Food and Drug Administration, Ministry of Health and Welfare, Taiwan, 2013-2015
  • Officer, Medical Review and Pharmaceutical Benefits Division, National Health Insurance Administration, Ministry of Health and Welfare, Taiwan, 2015-present

Yashaswi Gupta
Medical Science Liaison
Novo Nordisk, Singapore

Currently working as a medical science liaison at Novo Nordisk Singapore, Dr Yashaswi Gupta is an expert at analysing clinical data to obtain commercial insights. Armed with medical & management degrees, her real strength lies in providing rich insights to healthcare professionals through latest scientific & clinical data. She has handled entire project management activities for clinical trials in different parts of Asia. Her diverse experience in healthcare consulting, clinical research, and medical affairs allows her to grasp key opportunities for launching a new product. Passionate about developing new & innovative ways to address constraints faced in clinical trials, she works closely with multi-disciplinary teams at Novo Nordisk to drive KOL engagement and to support research initiatives.